

TriMark Publications

July 2007

Volume: TMRCTHER07-0701



CELL THERAPY MARKETS

(SAMPLE COPY, NOT FOR RESALE)

Trends, Industry Participants, Product Overviews and Market Drivers

TABLE OF CONTENTS

1. Overview	9
1.1 Statement of Report	9
1.2 About this Report	9
1.3 Scope of the Report	11
1.4 Objectives	11
1.5 Methodology	11
1.6 Executive Summary	12
2. Overview of the Science of Cell Therapy	15
2.1 Cell Therapy Technologies	15
2.1.1 Stem Cell Therapies	16
2.1.2 Umbilical Cord Blood Stem Cell Transplant	18
2.1.3. Cord Blood Collection, Transfusion and Storage Market	18
2.1.4 Cell Therapy and Related Technologies	23
2.2 Organ Transplantation to Cell Therapy	23
2.3 Sources of Cells for Therapy	25
2.4 Types of Cells Available for Therapy	28
2.4.1 Cells and Protein/Gene Therapy	29
2.4.2 Cell Therapy and Regenerative Medicine	29
2.4.3 Cells Therapy and Tissue Engineering	29
2.5 Cell Therapy Compared to Small Molecule Drugs, Biologics and Tissue Engineered Products	29
2.6 What Conditions are Amenable to Cell Therapy and Why?	30
2.6.1 Wounds and Burns	30
2.6.2 Aesthetic Medicine: Botox and Collagen	33
2.6.3 Cell Therapy for Bones and Joints	34
2.6.4 Blood Component Therapy	35
2.6.5 Immunotherapy for Cancer	36
2.6.6 Cardiovascular Disorders	36
2.6.7 Diabetes Mellitus	38
2.6.8 Neurological Disorders	39
2.6.9 Urinary Incontinence	40
2.6.10 Cells for Drug Discovery	41
2.7 Properties of Stem Cells and Their Classification	41
2.8 Stem Cell Differentiation	45
2.9 Stem Cell Therapy	46
2.10 Market Opportunity in the Stem Cell Marketplace	47
2.11 Potential Stem Cell Commercial Applications	49
2.11.1 Cord Blood Stem Cells and Cord Blood Stem Cell Banking: Current Market Environment and Opportunity	49
2.11.2 Qualitative and Quantitative Trends in the Stem Cells Space	53
2.11.3 Utilization of the Different Classes of Stem Cells	56
2.11.4 Quantitative Metrics of the Stem Cell Research Marketplace: Number of Experiments Performed, Research Spending Trends and Growth	57
3. The Cell Therapy Market	62
3.1 Market Overview	62
3.2 The Overall Cell Therapy Market Opportunity	62
3.3 Stem Cell Therapies	62
3.3.1 Cell Therapy/Regenerative Therapy Markets	65
3.3.2 Market Size According to Geographical Areas	66
3.4 Competitive Landscape of the Stem Cells Marketplace	66
3.4.1 Evolution of Research Activities with the Different Types of Stem Cells: Current Usage Trends and Usage in 12 to 18 Months	67
3.4.2 Types of Research Activities the End-User Community Performing with the Different Types of Stem Cells	69
3.4.3 Challenges Facing Stem Cell Researchers	73
3.4.4 Market Drivers	77
3.4.5 Research Questions Being Addressed in the Stem Cells Space	78
3.4.6 Focus on Cancer Stem Cells	78
3.4.7 Summary of Challenges and Opportunities in the Stem Cells Space Based on TriMark's Analysis	79
3.4.8 Unmet Product Needs in the Stem Cells Research Space and Licensing/IP Constraints	79
3.5 Competitive Landscape	81
3.5.1 Cell Therapy Market	81
3.5.2 Stem Cells Marketplace	82
3.6 Market Shares of Companies Offering Different Stem Cells	82
3.7 SWOT Analysis of the Major Stem Cell Market Segments	87
3.8 Market Size and Forecasts	90
3.8.1 The Research Market	90

3.8.2 Cell Therapy/Regenerative Therapy Markets 91

4. The Technology of Cell Therapy 93

4.1 Growing Cells-An Overview from Source to Product 93

4.2 Cell Culture 94

4.2.1 Cell Culture Process 94

4.2.2 Cell Culture Applications 94

4.2.3 Types of Mammalian Cultures 95

4.2.4 Plant Cell Culture 95

4.2.5 Commercialization of Cell Culture Products 95

4.2.6 Companies in Cell Culture Technology 96

4.3 Cell Lines 96

4.4 Large Scale Manufacturing 97

4.5 Making Product, Shipping, Distribution and Storage 98

4.6 Quality Control and Safety 98

4.7 Delivery Systems for Cell Therapy 99

4.8 Basic Technologies for Cell Therapy 100

4.8.1 Flow Cytometry and Cell Sorting 100

4.9 Cell Separation Techniques 105

4.9.1 Density-Based Isolation Methods 105

4.9.1.1 Ficoll-hypaque-based Density Gradient System NIM2 105

4.9.1.2 Lymphocyte Separation Medium 105

4.9.1.3 Density Gradient Media 105

4.9.2 Micro Sieves 105

4.9.3 Antibody-based Cell Separation Techniques 106

4.9.4 Magnet Sorting 107

4.9.5 Automated Separation Procedures 109

4.9.6 Aldesorter System for Isolation of Stem Cells 109

4.10 Cell Preservation Technology 110

4.11 Selective Expansion of T Cells for Immunotherapy 110

4.12 Devices for Delivery of Cell Therapy 111

4.12.1 Artificial Cells 111

4.12.2 Cell Encapsulation 111

4.12.2.1 Range of Therapeutic Treatments 112

4.12.2.2 Technical Barriers 112

4.12.2.3 Current Challenges 112

4.12.3 Therapeutic Applications of Encapsulated Cells 115

4.12.3.1 Cancer Therapy 115

4.12.3.2 Therapeutic Genes 118

4.12.3.3 Retinal Disease 119

4.12.4 Use of Microencapsulated Genetically Modified Cells 119

4.12.5 Nanoparticle-Aptamer Bioconjugates 120

5. Stem Cells 121

5.1 Basic Properties of Stem Cells and Their Classification 121

5.1.1 Embryonic Stem Cells 121

5.1.2 Embryonic Germ Cells 121

5.2 Sources of Stem Cells 122

5.3 Challenges Facing Stem Cell Researchers 123

5.4 Stem Cells for Drug Toxicity Screening 125

5.5 Market Analysis of the Stem Cells Space 126

6. Clinical Applications of Cell Therapy 127

6.1 Cell Therapy for Hematological Disorders 127

6.1.1 Hematopoietic Cells for Hematologic Diseases and to Prevent Immune Rejection 127

6.1.2 Hematopoietic Cytokines 128

6.1.3 Prochymal™ for the Treatment of Acute Graft versus Host Disease 129

6.1.4 Cell/Gene Therapy of Hemophilia B 130

6.1.5 Ex Vivo Cell/Gene Therapy of Hemophilia A 131

6.1.6 Therapies for the Hemophilia Market 133

6.1.7 Stem Cell Transplant for Sickle Cell Anemia 134

6.1.8 Modified Hematopoietic Stem Cells for Chronic Acquired Anemias 135

6.1.9 Stem Cell Therapy of Hemoglobinopathies 135

6.1.10 Future Prospects of Cell Therapy of Hematological Disorders 136

6.2 Cell Therapy for Immunological Disorders 136

6.2.1 Treatment of Crohn's Disease with Stem Cells 136

6.3 Cell therapy for Diabetes Mellitus 137

- 6.3.1 Islet Cells for Diabetes 137
- 6.4 Cell Therapy for Liver Disorders 137
 - 6.4.1 About Liver Disease 137
 - 6.4.2 Technology Summary 137
- 6.5 Cell Therapy for Renal Disorders 138
 - 6.5.1 Human Renal Epithelial Cells Administered Ex Vivo 138
- 6.6 Cell Therapy for Disorders of Bones and Joints 138
 - 6.6.1 Osteoblasts for Osteoporosis and Non-Union Bone Fractures 138
 - 6.6.2 Chondrocytes for Osteoarthritis and the Use of hESCs 139
 - 6.6.3 Knee Injury Treatment for Meniscectomy Patients Using Mesenchymal Stem Cells 139
- 6.7 Wound Healing: Skin and Soft Tissue Repair 139
 - 6.7.1 Autologous Living Cell Therapy 139
 - 6.7.2 Cell Therapy for Corneal Repair 140
 - 6.7.2.1 Current Clinical Status for Cornea Disease and Transplant 140
 - 6.7.2.2 Regenerative Cornea Product from Cellseed 141
- 6.8 Role of Cells in Tissue Engineering and Reconstructive Surgery 141
- 6.9 Cell Therapy for Cardiovascular Disorders 141
 - 6.9.1 Introduction to Cardiovascular Disorders 141
 - 6.9.1.1 Myocardial Infarction (Heart Attack) 141
 - 6.9.1.2 Congestive Heart Failure (CHF) 142
 - 6.9.1.3 Heart Failure Classification 142
 - 6.9.1.4 Diagnosis and Management of Heart Failure 143
 - 6.9.1.5 Drug Therapies 143
 - 6.9.1.6 Bi-ventricular Pacers 143
 - 6.9.1.7 Heart Transplantation and Other Surgical Procedures 144
 - 6.9.1.8 Ventricular Assist Devices 144
 - 6.9.1.9 Market Potential 145
 - 6.9.1.10 Limitations of Current Therapies for Myocardial Ischemic Disease 145
 - 6.9.2 Sector Overview of Cell Based Cardiac Repair 145
 - 6.9.2.1 Categories of Cell Types for Cell Therapy 146
 - 6.9.2.1.1 Autologous Skeletal Myoblasts 146
 - 6.9.2.1.2 Cardiocytes 147
 - 6.9.2.1.3 Mesenchymal Stem Cell (MSC) 148
 - 6.9.2.1.4 Bone Marrow Derived Stem Cells 148
 - 6.9.2.1.5 Fetal Cardiomyocytes 148
 - 6.9.2.1.6 Smooth Muscle Cells 148
 - 6.9.2.1.7 Immortalized Myoblasts 148
 - 6.9.2.1.8 Syngeneic Skeletal Myoblasts 148
 - 6.9.2.1.9 Fibroblasts 148
 - 6.9.2.1.10 Embryonic Stem Cell 149
 - 6.9.2.1.11 Bone Marrow Derived Stromal Cells 149
 - 6.9.2.2 Current Cell Therapies for Myocardial Ischemic Disease 150
 - 6.9.2.2.1 Cardiomyocytes for Heart Disease 150
 - 6.9.2.2.2 Mesenchymal Stem Cells (MSCs) Provacel™, (Osiris Therapeutics) 150
 - 6.9.2.2.3 Living Regenerative Cardiac Patch (Cellseed) 151
 - 6.9.2.2.4 Bioheart's MyoCell 151
 - 6.9.2.2.5 Viacell's Unrestricted Somatic Stem Cells (USSCs) 154
 - 6.9.2.2.6 Mytogen's Autologous Myoblasts 155
 - 6.9.3 Research Methods for Delivery of Cells to the Heart 155
 - 6.9.3.1 Cell Transplantation for Cardiac Repair 155
 - 6.9.3.2 Using Nanofibers to Deliver Insulin Growth Factor 155
 - 6.9.4 Role of Stem Cells in Repair of the Heart 156
 - 6.9.4.1 Cardiac Autologous Stem Cells 156
 - 6.9.4.1.1 Expansion of Stem Cells 156
 - 6.9.4.1.2 Role of ESCs in Repair of the Heart 158
 - 6.9.4.1.3 Transplantation of BMPCs 158
 - 6.9.4.1.4 Transplantation of CMPCs 159
 - 6.9.4.1.5 Transplantation of hESCs 159
 - 6.9.4.1.6 Transplantation of Skeletal Myoblasts 160
 - 6.9.4.1.7 Transplantation of Autologous Angiogenic Cell Precursors 160
 - 6.9.4.1.8 Regeneration of Chronic Myocardial Infarcts by HSC Therapy 161
 - 6.9.4.1.9 Transplantation of Adipose-Derived Stem Cells 162
 - 6.9.4.1.10 Intracoronary Infusion of Bone Marrow-Derived Cells for AMI 163
 - 6.9.4.1.11 Human Mesenchymal Stem Cells for Cardiac Regeneration 163
 - 6.9.4.1.12 Simultaneous Transplantation of Autologous MSCs and Skeletal Myoblasts 163
 - 6.9.5 Role of Genetically Modified Cells 164
 - 6.9.5.1 Gene Therapy Using Modified Stem Cells 164

- 6.9.5.2 Use of Cells Secreting Vascular Endothelial Growth Factor 166
- 6.9.6 Cell Therapy for Congestive Heart Failure 166
 - 6.9.6.1 Angiocyte Gene Therapy for Congestive Heart Failure 166
 - 6.9.7 Role of Cell Therapy in Cardiac Arrhythmias 166
 - 6.9.7.1 Genetically Modified Cell Grafts 167
 - 6.9.7.2 Cardiomyocyte Cell Grafts 167
 - 6.9.7.3 Antiarrhythmic Potential of Cell Therapy Strategies 168
 - 6.9.7.4 Vectors for Gene Therapy 169
 - 6.9.7.5 Methods of Gene Delivery 169
 - 6.9.7.6 Gene Therapy in Cardiac Arrhythmias 169
 - 6.9.7.7 Current Problems with Gene Therapy 169
 - 6.9.8 Cell Therapy for Cardiac Tissue Engineering of Blood Vessels with Cells 170
 - 6.9.8.1 Fetal Cardiomyocytes Seeding in Tissue-Engineered Cardiac Grafts 170
 - 6.9.9 Competitive Landscape for Cell Therapy Based Cardiovascular Products 170
 - 6.9.10 Evaluation of Cell Therapy as Therapy for Heart Disease 171
- 6.10 Cell Therapy for Cancer 171
 - 6.10.1 Introduction 171
 - 6.10.2 Cell Therapy Technologies for Cancer 171
 - 6.10.3 Cellular Immunotherapy for Cancer Treatments for Cancer by ExVivo Mobilization of Immune Cells 172
 - 6.10.4 Alternative Cancer Treatment Market 172
 - 6.10.5 Autologous Tumor Cell Vaccines and Dendritic Cell Therapy 173
 - 6.10.6 The Use of Dendritic Cells for Cancer Vaccination 177
 - 6.10.6.1 Collection of Cells 177
 - 6.10.6.2 Basics of Dendritic Cell Vaccines 178
 - 6.10.6.3 Dendritic Cells Treated with Purified Tumor Antigen 179
 - 6.10.6.4 Stimulation of Immature Dendritic Cells to Become Mature Dendritic Cells 179
 - 6.10.6.5 Cell Fragments of Dendritic Cells Primed with Tumor Cell Antigens 180
 - 6.10.7 Gene Therapy 181
 - 6.10.8 Stem Cell-Based Anticancer Therapies 181
 - 6.10.9 Other Cell Therapy Vaccines 181
 - 6.10.10 Stem Cell Transplantation in Cancer 182
 - 6.10.10.1 Peripheral Blood Stem Cell Transplantation 182
 - 6.10.10.2 Autologous Stem Cell Transplantation 184
 - 6.10.10.3 Complications of Stem Cell Transplants in Cancer 185
 - 6.10.10.4 Mesenchymal Stem Cell Transplantation in Cancer 185
 - 6.10.10.5 Umbilical Cord Blood Transplant for Leukemia 185
 - 6.10.10.6 Hesc-Derived NK Cells for Treatment of Cancer 186
 - 6.10.11 Innovations in Cell-Based Therapy of Cancer 186
 - 6.10.11.1 Cancer Therapy Based on NK-92 Cells 186
 - 6.10.11.2 Myoblast Mediated Gene Therapy 187
 - 6.10.12 Cancer Stem Cells 187
 - 6.10.13 Mesenchymal Stem Cells for the Treatment of Gliomas 187
 - 6.10.14 Companies Involved in Cell-Based Cancer Therapy 188
 - 6.10.15 Stem Cell-Based Anti-Cancer Therapies 191
- 6.11 Cell Therapy for Neurological Disorders 192
 - 6.11.1 Oligodendrocytes for Spinal Cord Injury and Dopaminergic Neurons for Parkinson's Disease 192
 - 6.11.2 Neural Stem Cells as a Treatment for Neuronal Ceroid Lipofuscinosis 192
 - 6.11.3 Epilepsy and Neuropathic Pain Markets 192
 - 6.11.4 Delivery of Naturally Occurring Neurotrophic Factors 192
 - 6.11.5 Repairing the Nervous System 193
 - 6.11.6 Genes Permanently Incorporated into Targeted Cells 193
 - 6.11.7 Neurological Disorders Responding to Neurotrophic Factors 194
 - 6.11.8 Ceregene's Products 194
 - 6.11.9 Parkinson's Disease 195
 - 6.11.9.1 Introduction 195
 - 6.11.9.2 Market Opportunity 195
 - 6.11.9.3 Stem Cell Line for Functional Dopaminergic Neurons 195
- 6.12 Cell Therapy for Stroke 197
 - 6.12.1 Introduction 197
 - 6.12.2 Market Opportunity 197
 - 6.12.3 Stem Cell Therapy for Chronic Stroke Disability 197
- 6.13 Cell Therapy for Dental Treatments 198
- 6.14 Gene Therapy 198
 - 6.14.1 Vehicles for Gene Transfer 198
 - 6.14.2 Viral Vectors for Gene Therapy 199
 - 6.14.3 Nonviral Vectors: Liposomes 200
 - 6.14.4 Gene Therapy for Hematopoietic Derived Diseases 200

6.15 hESC-Derived Hepatocytes for Drug Screening and Toxicology	201
7. Ethics, Regulation and Funding	203
7.1 Ethics	203
7.2 The U.S. Position on hESC Research	205
7.3 Regulation and Legislation	206
7.3.1 Regulations on Stem Cell Research	206
7.3.2 Regulation of Tissue Engineered Products	208
7.4 Investment	209
7.5 Interdisciplinary and Public-Private Partnerships	210
7.6 Corporate Partnerships	210
7.6.1 ReNeuron and CellSeed Collaboration Using ReNcell™ Liver Cell Lines	210
7.6.2 Plureon Corporation in Agreement with BD	211
7.6.3 Icoria Inc. Research Agreement with Vesta Therapeutics	211
7.7 Corporate Mergers	211
7.7.1 GenVec's Acquisition of Diacrin, Inc.	211
7.7.2 Genvec Transferred its Cell Transplantation Assets to Mytogen, Inc.	211
7.8 European Regulation on Advanced Cell Therapies	212
7.9 Processing Autologous Cell Products-Discussing the Regulatory and Commercial Impact of Patient-Specific Therapies	213
7.10 Stem Cell Research Funding	214
8. Future Directions in Cell Therapy	215
8.1 Cell Therapy Future Markets According to Therapeutic Area	215
8.1.1 Brain and Central Nervous System Applications	215
8.1.2 Cardiology Applications	218
8.1.3 Diabetes Applications	221
8.1.4 Tissues and Organs	222
8.1.5 Other Applications	222
8.2 Unmet Market Needs in Cell Therapy	223
8.3 Future Prospects of Cell Therapy	223
8.3.1 Autologous Stem Cells	223
8.3.2 Pluripotent Stem Cells Lines	224
8.3.3 Angiogenesis	224
8.3.4 Reprogramming Stem Cells	224
8.4 Clinical Trials in Cell Therapy	224
8.5 Analytical Tools for Cell Therapy	226
8.6 Ethical Concerns of Cloning for Reproductive Purposes	226
8.6.1 Ethical Concerns	226
8.6.2 Policy and Regulation	226
8.7 Cloning for the Isolation of Human ES Cells	227
8.7.1 Ethical Concerns	227
8.7.2 Policy and Regulation	227
8.8 Somatic Cell Nuclear Transfer Generating Pluripotent Stem Cells	227
8.9 Funding of Stem Cell Research from Non-Federal Sources	228
8.10 Industry Challenges for Cell Therapy Manufacturing	228
8.10.1 Cost Challenges to Manufacturing Processes	228
8.10.2 Supply Challenges for Current Manufacturing Processes	228
8.11 Future Prospects of Cell Therapy	228
8.12 Challenges for Cell Therapy	229
8.13 Therapeutic Cloning	229
8.14 Future Market Potential of Adult Versus Embryonic Stem Cells	230
8.15 Challenges of Developing a Cell Therapy Product Compared to a Conventional Drug Product	231
8.16 Transition from a Technology Driven Company to a Product Driven Company	231
8.17 Exploiting Technology Platforms for Commercial Success	231
8.18 At What Point Do You Seek a Partner in Cell Therapy Development	232
8.19 Cell and Tissue Therapies Product Development and Manufacture	232
8.19.1 What Commercialization Models are Emerging to Cope with Complex Manufacturing Required by Cell Therapies?	232
8.19.2 Optimizing Product Development, Manufacture and Commercialization of Autologous and Allogeneic Cell Therapies	232
9. Company Profiles	234
9.1 Aastrom Biosciences	234
9.2 Advanced Cell Technology	235
9.3 Advanced Cell Therapeutics	235
9.4 Aldagen	235
9.5 AllCells, LLC.	236
9.6 AmCyte	236
9.7 Arthro Kinetics	236

- 9.8 AstraZeneca 236
- 9.9 Australian Stem Cell Centre 237
- 9.10 Axordia 237
- 9.11 BioE 238
- 9.12 Bioheart 238
- 9.13 BioTransplant Incorporated 239
- 9.14 BrainStorm Cell Therapeutics 239
- 9.15 Cambrex 240
- 9.16 Cardio3 240
- 9.17 Cartela 240
- 9.18 Cellartis 241
- 9.19 Cellerant Therapeutics 241
- 9.20 CellSeed Inc. 241
- 9.21 Cellular Dynamics International 241
- 9.22 Ceregene, Inc. 242
- 9.23 Cryo-Cell International 242
- 9.24 Cytori Therapeutics 243
- 9.25 ES Cell International 244
- 9.26 Fraunhofer Institute for Cell Therapy and Immunology 244
- 9.27 Gamida Cell Therapeutics 244
- 9.28 GE Healthcare 245
- 9.29 GenVec, Inc. 245
- 9.30 Geron 246
- 9.31 GlaxoSmithKline 247
- 9.32 Intercytex 249
- 9.33 Invitrogen 249
- 9.34 Institute for Stem Cell Research, University of Edinburgh 250
- 9.35 Isolagen 250
- 9.36 Lexicon Genetics 251
- 9.37 Lund Stem Cell Center, Lund University 252
- 9.38 MaxCyte 252
- 9.39 Miltenyi Biotec 253
- 9.40 NeuroNova 253
- 9.41 Norwegian Center for Stem Cell Research 254
- 9.42 NovaThera 254
- 9.43 NsGene 254
- 9.44 Osiris Therapeutics 255
- 9.45 Pfizer 255
- 9.46 Plureon 257
- 9.47 Pluristem Life Systems 257
- 9.48 Progenitor Cell Therapy, LLC 258
- 9.49 Regenerative Medicine Network (RegMedNet), University of Leipzig 258
- 9.50 RenaMed Biologics 258
- 9.51 ReNeuron 258
- 9.52 StemCells, Inc. 259
- 9.53 Stem Cell Innovations 259
- 9.54 Stem Cell Sciences 260
- 9.55 StemCell Technologies 260
- 9.56 Thermogenesis 260
- 9.57 TiGenix 261
- 9.58 Tissue Engineering and Regenerative Medicine Centre, Imperial College London 261
- 9.59 UK Stem Cell Bank 261
- 9.60 UK Stem Cell Foundation 262
- 9.61 ViaCell 262
- 9.62 Vesta Therapeutics, Inc. 262
- 9.63 VistaGen Therapeutics 263
- 9.64 Wolfson Centre for Age-Related Diseases, King's College, London 263
- 9.65 AlphaCord 263
- 9.66 Celgene 263
- 9.67 Cord Blood Registry 264
- 9.68 Angiogene 265
- 9.69 EntreMed 265

Appendix 266

- Sources of Umbilical Cord Blood for Stem Cell Research 266
- National Marrow Donor Program 266
- For Profit Storage of Cord Blood 266

Stem Cells from Frozen Embryos 267
 Stem Cell Policy Statement 267
 Glossary of Terms in Cell Biology 268

LIST OF TABLES

Table 2.1: U.S. Companies Involved in Cord Blood Banking	21
Table 2.2: U.K. Companies Involved in Cord Blood Banking	22
Table 2.3: Waiting List for Organ Transplants in U.S.	25
Table 2.4: Number of Organ Transplants Carried out in U.S., January-March 2006	25
Table 2.5: Sources of Cells for Therapy and Other Applications	28
Table 2.6: U.S. Wound Care Market, 2003-2012	31
Table 2.7: Stem Cell Therapeutics for Orthopedic Disease in Development	35
Table 2.8: Cellular Therapies in Orthopedics Trauma and Fracture Markets	35
Table 2.9: Stem Cell-based Therapeutics for Cardiac and Ischemic Diseases in Development	37
Table 2.10: Stem Cell-Based Therapeutics for Vascular Diseases in Development	38
Table 2.11: Stem Cell Therapeutics for Type I Diabetes in Development	39
Table 2.12: Stem Cell Therapeutics for Neurological Disease in Development	40
Table 2.13: Key Properties of Stem Cells	42
Table 2.14: Sources of Human Stem Cells	42
Table 2.15: The Different Types of Stem Cells and their Properties	44
Table 2.16: Adult Stem Cell (ASC) Differentiation Properties	45
Table 2.17: Characteristics of Different Stem Cell Types and Associated Market Opportunities	48
Table 2.18: Segmentation of the Stem Cell Market by Type/Lineage of Stem Cell	49
Table 2.19: Selected Cord Blood Banks in the U.S.	52
Table 2.20: Selected Companies in the Cord Blood Stem Cell Technology and Therapeutics Development Space	53
Table 3.1: Worldwide Cell Therapy Markets, 2005-2012	62
Table 3.2: Worldwide Stem Cell, Cytokine, and Growth Factor Cell Therapy Markets, 2005-2012	63
Table 3.3: The World Market for Stem Cell Products and Services, 2005-2012	65
Table 3.4: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells	67
Table 3.5: Breakout of the Stem Cell Research Market: Research Efforts with Different Types of Stem Cells in 12 to 18 Months	67
Table 3.6 Publicly-Held Stem Cell Companies	83
Table 3.7: Market Shares of Companies/Institutions Offering Different Stem Cells to Researchers	83
Table 3.8: Market Shares of Companies/Institutions Offering Reagents for Stem Cell Research	84
Table 3.9: Privately-Held Stem Cell Companies	84
Table 3.10: Product and Custom Service Providers in the Stem Cells Space	85
Table 3.11: Cord Blood Stem Cell Companies	85
Table 3.12: Adult Stem Cell Companies	85
Table 3.13: Reagents, Media and Consumable Companies	86
Table 3.14: Stem Cells Research Market Forecast, 2006-2011	91
Table 4.1: Worldwide Market for Flow Cytometry Instruments and Reagents, 2000-2010	102
Table 4.2 Leading Players in Flow Cytometry Instrumentation	103
Table 5.1: Leading Stem Cell Companies	126
Table 6.1: Hematopoietic Cytokines	128
Table 6.2: Skin Rejuvenation (Aesthetics) Markets, 2005-2012	140
Table 6.3: Burn Scars Markets, 2005-2012	140
Table 6.4: Acne Scars, 2005-2012	140
Table 6.5: NYHA Classifications for Stages of Heart Failure	142
Table 6.6: Worldwide Market for Cardiac Care Therapeutics, 1999-2010	143
Table 6.7: Examples of Cell Types Used in Cardiac Repair	146
Table 6.8: Clinical Trials of MyoCell	153
Table 6.9 : The Common Metrics Used to Evaluate the Efficacy of These Therapies Include	154
Table 6.10: Stemline™ Platform Media for Expansion and Maturation of Stem Cells	156
Table 6.11: Gene Transfer Vehicles	199
Table 7.1: Investment in Stem Cell Research in Different Countries	209
Table 7.2: International Location of hESC Lines	212
Table 7.3: Unpublished Lines (Not Peer-Reviewed)	212
Table 8.1: Delivery of Cells for Heart Repair Technologies	220

LIST OF FIGURES

Figure 2.1: Release of Leukocytes into the Bloodstream	17
Figure 2.2: Derivation of Embryonic Stem Cells (ESCs) from the Inner Cell Mass of Blastocysts	43
Figure 2.3: Classification of Stem Cells: Embryonic Stem Cells versus Adult Stem Cells	44
Figure 2.4: Somatic Cell Nuclear Transfer (SCNT)	46

Figure 2.5: Segmentation of the Stem Cells Marketplace Based upon Commercial Offerings-Products and Services	50
Figure 2.6: Geographical Breakout of Stem Cell End-user Survey Respondents	54
Figure 2.7: Affiliation (Pharma, Biotech, Academic/University) of Stem Cell End-user Survey Respondents	54
Figure 2.8: Most of the Survey Respondents are Studying Stem Cells or Using Stem Cells in Their Research	55
Figure 2.9 Length of Time Survey Respondent Pool Studying Stem Cells or Using Stem Cells in Their Research Activities	55
Figure 2.10: Utilization/Research with Different Stem Cell Types	56
Figure 2.11: Range of Number of Experiments Involving Stem Cells Conducted per Week	57
Figure 2.12: Do the two Sub-Populations of Researchers Occupying the Two Ends of the Throughput Scale Exhibit Differences with Respect to Usage of Different Stem Cell Types?	58
Figure 2.13: How Much Research Dollars Are Spent Monthly on Research/Studies with Different Stem Cell Types	59
Figure 2.14: Growth of Research Spending in Various Segments of the Stem Cells Space (Defined by Stem Cell Type)	60
Figure 3.1: Global Forecast of Revenues for Stem Cell and Cytokine Therapies in Regenerative Medicine, 2003-2010	63
Figure 3.2: Stem Cell Research Market, 2006-2011	64
Figure 3.3: Growth in End-User Utilization of the Various Different Stem Cell Types	66
Figure 3.4: Breakout of the Stem Cell Research Market: Current Research Efforts with Different Types of Stem Cells	68
Figure 3.5: Breakout of the Stem Cell Research Market: Research Efforts with Different Types of Stem Cells in 12 to 18 Months	69
Figure 3.6: Broad Classification of Research Activities Being Performed with Stem Cells by Researchers	70
Figure 3.7: Current End-User Utilization Category of Adult Stem Cells (ASCs)	71
Figure 3.8: Current End-User Utilization Category of Human Embryonic Stem Cells (hESCs)	71
Figure 3.9: Current End-User Utilization Category of Human Cord Blood Stem Cells	72
Figure 3.10: Current End-User Utilization Category of Animal Stem Cells	72
Figure 3.11: Current End-User Utilization Category of Cancer Stem Cells	73
Figure 3.12: Challenges in the Study or Utilization of Adult Stem Cells (ASCs)	74
Figure 3.13: Challenges in the Study or Utilization of Human Embryonic Stem Cells (hESCs)	75
Figure 3.14: Challenges in the Study or Utilization of Human Cord Blood Stem Cells	75
Figure 3.15: Challenges in the Study or Utilization of Animal Stem Cells	76
Figure 3.16: Challenges in the Study or Utilization of Cancer Stem Cells	76
Figure 3.17: Top Unmet Needs in Commercial Products in the Stem Cells Research Space	80
Figure 3.18: Stem Cells Research Market, 2006-2011	91
Figure 4.1: Cell Microencapsulation: Promise and Progress	111
Figure 6.2: Ceregene Pipeline of Products	194
Figure 7.1: FDA Review Centers	205
Figure 7.2: World Map of Stem Cell Regulations	208

1. Overview

1.1 Statement of Report

The purpose of this report is to describe the specific market segments of the cell therapy sector. This study reviews all of the generally accepted clinical and analytical methods that are currently in use today for implementing cell therapy techniques. It examines this new scientific technique and their reagents and supplies as utilized in hospitals, research laboratories and biotechnology companies.

1.2 About this Report

The two most important areas where cell therapy is used are in the hospital and the clinic. Growth areas of interest for cell therapy are biotechnology platforms. The emphasis in this analysis is on those companies and products that are actively developing and marketing instrumentation, reagents and supplies for cell therapy. The reader should consult other TriMark Publications reports at <http://www.trimarkpublications.com> for a detailed discussion of the important individual market segments, which are related to the biotech.

The main objectives of this analysis are:

- Identifying viable technology drivers through a comprehensive look at platform technologies for cell therapy testing.
- Understanding the different sectors of cell therapy testing, such as growing cells, cell sources and the manufacturing segment; and, separately, looking at a description of the instruments, reagents and supplies marketed by major companies in each segment. The report discusses the market size, growth rates and market components for instruments and reagents, controls and consumables used in this area.
- Obtaining a complete understanding of the individual cell therapy platforms from their basic principles to their clinical applications.
- Discovering feasible market opportunities by identifying high-growth applications in different therapeutic areas, focusing on the biggest and expanding markets.
- Examining on global industry development through an in-depth analysis of the major world markets for cell therapy measurement technology, including growth forecasts.
- Presenting market figures regarding the current value of cell therapy testing, market projections, market share, key players and sector growth rates. The source of this information is the most current data derived from the global pharmaceutical industry.

By purchasing this report, you will have:

- An understanding of the most exciting cell therapy market segments, current and future.
- The latest information on leading products and research and development (R&D) initiatives.
- Familiarity with recent developments and their effects on selected markets.
- Knowledge of the cell therapy market as an area of growth, research and investment.
- An extensive review of the market for clinical cell therapy equipment and supplies used in the clinical hospital market for testing cell therapy concentrations.
- Details on the market for screening reagents and instruments for analysis of individual components in blood, serum or plasma.
- Defined dollar volume of sales, both worldwide and in the U.S. of the market, and analysis of the factors that influence the size and the growth of the market segments.

Key questions answered in this study:

- How can cell therapy measuring tools and technologies facilitate improved patient care?
- What are the main types of cell therapy technologies that are currently available?
- Who are the current key players in this marketplace?
- Which cell therapy market areas have the greatest potential for growth?
- What is the current state of the cell therapy market?
- Which biotechnology and diagnostic companies are investing in new cell therapy technology platform solutions?
- What are the main cell therapy business strategies adopted by leading companies?
- What are the benefits of various cell therapy technology platforms?
- Who holds the proprietary rights to the cell therapy market technology platforms?
- How is this technology currently being applied and utilized?
- In the U.S., Japan and the E.U., what regulatory processes apply to cell therapy technologies?
- How will new cell therapy technologies reduce healthcare expenditures?
- How will new cell therapy technologies affect R&D spending?

This examination contains:

- Detailed analysis of recent trends in the cell therapy marketplace.
- In-depth profiles of the leading companies with cell therapy tools and technologies.
- Forecasts for the cell therapy market in the biotechnology and diagnostic industries.
- Views and principles on the cell therapy industry from leading industry experts.
- Analysis of potential new cell therapy applications in the clinical sector.
- Market predictions and trends analysis concerning U.S. expenditures on cell therapy solutions.
- Projections of cell therapy market sizes for European and Asian markets.
- Projections for future applications of non-invasive tests in cell therapy related screening.
- Analysis of commercial cell therapy business strategies, such as co-branding.
- The latest news and M&A developments in the cell therapy marketplace.
- A comprehensive overview and insight into cell therapy business strategies for growth in foreign markets.
- An in-depth examination of the subsections of each cell therapy market segment is conducted.
- An overview that introduces the various kinds of stem cells, gives definitions, and discusses political, regulatory aspects, and the major developments.
- Analysis of applications including current and potential cytokine and cell therapies.
- A discussion of current products, as well as many that are still in clinical trials.
- An industry structure analysis including companies in the field and their focus.

Analysis includes charts and graphs measuring product growth and trends within the marketplace. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided. Also, this study will:

- Assess cell therapy market drivers and bottlenecks, from medical and scientific community perspectives.
- Discuss the potential benefits of cell therapy for various sectors of the medical and scientific community.
- Establish the current total market size and future growth of the cell therapy market and analyze the current size and growth of individual segments.
- Provide current and forecasted market shares by company.
- Discuss profit and business opportunities by segment.
- Provide strategic recommendations for near-term business opportunities.
- Assess current commercial uses of the cell therapy market.

1.3 Scope of the Report

This analysis emphasizes companies that are actively developing and marketing instrumentation, reagents and supplies for performing cell therapy tests. The reader should consult other TriMark Publications reports at <http://www.trimarkpublications.com> for detailed discussions of important individual market segments related to the protein analysis market, such as clinical chemistry testing, high-growth diagnostic test markets, blood gas and electrolytes, over-the-counter diagnostic testing markets, and point-of-care testing.

1.4 Objectives

The goal of this report is to review the market for cell therapy products using screening reagents and instruments for analysis of individual components in tissue samples, blood, serum or plasma. It defines the dollar volume of sales, both worldwide and in the U.S., and analyzes the factors that influence the size and the growth of the market segments. Also examined are the subsections of each market segment, including the research labs, hospital labs and commercial laboratories. Additionally, the numbers of institutions using this type of cell therapy and the factors that influence purchases are discussed. The study surveys almost all of the companies known to be marketing, manufacturing or developing instruments and reagents for the cell therapy market in the U.S. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position.

1.5 Methodology

This examination is based upon interviews with sales and marketing professionals of companies in the cell therapy marketplace. They were queried, some several times, about their companies' products and marketing strategies, as well as their overall thoughts about their industry segment. Information also was obtained from discussions with founders, CEOs and vice presidents of some of the companies discussed in the report. Descriptions of the laboratories and patient facilities were derived from interviews with laboratory directors and technologists in these areas.

Other sources of information included trade association publications and meetings, product brochures and catalogs, and company literature. We have also gathered statistical information from the U.S. government, the World Health Organization, and private foundations. Annual reports, 10k filings, and financial reports were used as the basis for data reported on publicly held companies. The author of this report is a Ph.D. in biochemistry with years of experience in science writing and as a medical industry analyst. The editor is a doctoral level clinical scientist. He has over thirty years of experience in laboratory testing and instrument and reagent development technology, as well as extensive experience in senior level positions in biotech and medical service companies.

Some of the statistical information was taken from Biotechnology Associates' databases and from TriMark's private data stores. The information set forth in this study was obtained from sources that we believe to be reliable, but we do not guarantee the accuracy, adequacy or completeness of any information, omission or for the results obtained by the use of such information.

Key information from the business literature was used as a basis to conduct dialogue with and obtain expert opinion from market professionals with regard to commercial potential and market sizes. Senior managers from major company players were interviewed for part of the information in this study. The information in this report is also based upon direct experience with sales and marketing professionals of companies in the point of care instruments and reagents market. People from many companies mentioned in this analysis were considered thoughtfully about their companies' products and marketing strategies, as well as their overall thoughts about their industry segment. The structure of the laboratory facilities was derived from familiarity with scientists and technologists working in these areas.

Primary Sources - TriMark collects information from hundreds of database tables and many comprehensive multi-client research projects and sector snapshots that we publish annually. We extract relevant data and analytics from TriMark's research of the past three years as part of this data collection. We also extract qualified data feeds from e-questionnaire responses and primary research responses for this compilation.

Secondary Sources - TriMark uses research publications, journals, magazines, newspapers, newsletters, industry reports, investment research reports, trade and industry association reports, government affiliated trade releases, and other published information as part of our secondary research materials.

The information is then analyzed and translated by the Industry Research Group into a TriMark study. The Editorial Group reviews the complete package with product and market forecasts, critical industry trends, threats and opportunities, competitive strategies and market share determinations. The report conclusions are verified through intensive interviewing of top ranking companies in the industry.

TriMark Publications Report Research and Data Acquisition Structure

The general sequence of research and analysis activity prior to the publication of every report includes the following items:

- Completing an extensive secondary research effort on an important market sector, including gathering all relevant information from corporate reporting, publicly available databases, proprietary databases, direct meetings and personal interviews with key personnel.
- Formulating a study outline with the assigned writer, including important items:
 - Market and Product Segment grouping and evaluating their relative significance.
 - Key competitors' evaluations, including their relative positions in the business and other relevant facts to prioritize diligence levels and assist in designing a primary research strategy.
 - End-user research to evaluate analytical significance in market estimation.
 - Supply chain research and analysis to identify any factors affecting the market.
 - New technology platforms and cutting edge applications.
- Identifying the key technology and market trends that drive or affect these markets. Assessing the regional significance for each product and market segment for proper emphasis of further regional/national primary and secondary research.
- Launching a combination of primary research activities, including two levels of questionnaires, executive-direct focused, company-specific, and region-specific communications to qualified and experienced senior executives worldwide.
- Completing a confirmatory primary research assessment of the report's findings with the assistance of Expert Panel Partners from the industry being analyzed.

1.6 Executive Summary

Cell therapy technologies and methods have already started to play an important role in the practice of medicine. Hematopoietic stem cell transplantation is replacing the old fashioned bone marrow transplants. Cell therapy is bound to become a part of medical practice. Unlike organs, cells are a potentially renewable resource for body repair. Advances in understanding cell biology, for instance, in the conditions needed for successful cell culture, and in the biochemical and genetic signals cells need for differentiation, have made cell therapy (including stem cell therapy) a scientific and clinical possibility.

Stem cells have two important properties that distinguish them from other kinds of cells; they can proliferate, possibly indefinitely, without changing their phenotype, and they can also spontaneously change—a process known as differentiation—into one or more new cell types. Differentiation takes place either directly or in several distinct steps. Cell therapy, including stem cell therapy, has the potential for healing and repairing the body. Many diseases, such as heart failure, stroke, Parkinson's disease, and diabetes, are marked by the loss of cells, which could be renewed by transplantation. Added to this, cells have applications in drug discovery as models for pre-clinical work that could complement or even replace animal testing. They are also an important tool in studies of basic human biology, which underpins the search for better medicines.

Cell therapy technologies overlap with those of gene therapy, cancer vaccines, drug delivery, tissue engineering and regenerative medicine. Various types of cells used, methods of preparation and culture, encapsulation and genetic engineering of cells are discussed. Sources of cells, both human and animal (xenotransplantation) are discussed. Methods of delivery of cell therapy range from injections to surgical implantation using special devices.

Much of the promise of cell therapy comes from stem cells, but this is still very much an emerging field with most activity being concentrated in universities, research institutes, and small biotech companies. While there are many clinical trials ongoing, most of these are with bone marrow derived stem cells and none with embryonic stem cells.

Cell therapy market drivers include:

- An aging population with both chronic health problems and an interest in aesthetic medicine (“feel better, look better”).
- Increase in diseases where existing drug therapy does not provide a cure, diabetes, Alzheimer’s disease, Parkinson’s disease, *etc.*
- Increased attention given to “incurable” neurodegenerative disease/trauma, *e.g.*, amyotrophic lateral sclerosis (a/k/a *Lou Gehrig’s* disease), spinal cord injury.
- Need for better models for pre-clinical testing in the pharmaceutical industry so they can more readily “fail early, fail cheaper”.
- Increased interest in aesthetic/cosmetic procedures—\$1.1 billion spent on Botox® in the U.S. last year, eight million Americans have cosmetic procedures each year and the market is growing in Europe.
- The life sciences/biotech industry is developing or has many of the tools for commercialization of cell therapy, *e.g.*, cell culture capacity, bioprocessing, cell surface markers, separation technologies, cell-based assays. These are currently dedicated to the manufacture of biologics (monoclonal antibodies, vaccines and recombinant proteins) but could readily be adapted.
- The growth of the biotech industry in the past decade has laid some of the groundwork for understanding safety and regulatory issues involved in taking a biological product like a cell therapy to market.

Cell therapy market barriers involve:

- For stem cells in particular, there is still a lack of basic understanding on what factors differentiate cells to the one of choice and keeps them differentiated, on how they engraft, survive, and carry out their function in therapy.
- It is not at all clear which stem cell and from what source might be the best therapeutic option or how “pure” a cell population should be. Nor is it clear if undifferentiated, lineage committed, or terminally differentiated cells ought to be used in therapy.
- There are technical issues over the cell expansion, large scale manufacture, storage and shipping of cell-therapy based products. Moreover, there is no clear route to the commercialization of stem cell therapy at the present time, although some companies can produce cells to GMP standards.
- The best method for delivery of cells into the body is still a subject for debate and further investigation.
- The correct dosage of cells to have a therapeutic effect is an issue.
- Safety issues involve whether the presence of animal components in the culture medium might introduce contamination, immunogenic responses to allogeneic (donor) cells, tumorigenic potential of stem cells.

- Ethical concerns and lack of harmonized regulation at national and international level surround the use of certain cells—especially those derived from human embryos or fetuses.
- The regulation of cell-based products remains unclear in many locations and there is a lack of harmony. They may be regulated as a medical device, a biologic or a medicinal product. New legislation is being discussed, both in Europe and the U.S. This uncertainty will have an adverse effect on reimbursement which could limit market expansion.
- Lack of investment in development after Phase 1 clinical trials. Media hype, especially on stem cells, may have led to over-expectation which may scare off some investors.
- For successful market development, culture change is needed—pharma reps will need a lot of training, and surgeons do not like to learn new methods of working. Products must be easy to use.

The value of the cell-based therapy markets was \$ [REDACTED] in [REDACTED], and is expected to increase to \$ [REDACTED] in [REDACTED], and \$ [REDACTED] in [REDACTED], growing at an annual rate of [REDACTED]%. The worldwide market for the important sub-sector of cell therapy, including stem cell, cytokine and growth factor therapies is estimated at \$ [REDACTED] in [REDACTED] and, rising at a compound annual growth rate (CAGR) of [REDACTED]%. The total market is expected to reach \$ [REDACTED] in [REDACTED].

The number of companies involved in cell therapy has increased remarkably during the past few years. More than [REDACTED] companies have been identified to be involved in cell therapy and [REDACTED] of these are profiled in part II of the report along with tabulation of [REDACTED] alliances. Of these, [REDACTED] are involved in stem cell therapy. The first off-the-shelf cell therapy approved by the FDA was for wound treatment. Recently, a bone morphogenic protein (BMP) has been approved for the acceleration of spinal fusions.